mFOLFIRINOX With or Without Stereotactic Body Radiotherapy in Locally Advanced Pancreatic Adenocarcinoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

92

Participants

Timeline

Start Date

August 14, 2021

Primary Completion Date

January 23, 2025

Study Completion Date

December 14, 2025

Conditions
Pancreatic AdenocarcinomaPancreatic Cancer Non-resectable
Interventions
RADIATION

SBRT+mFOLFIRINOX

Stereotactic body radiotherapy: 3500 cGy (5 fractions) mFOLFIRINOX, every 2 weeks Oxaliplatin, 85 mg/m2, intravenous, day 1 Leucovorin, 400 mg/m2, intravenous, day 1 Irinotecan, 150 mg/m2, intravenous, day 1 fluorouracil, 2,400 mg/m2, intravenous, day 1-2

DRUG

mFOLFIRINOX

mFOLFIRINOX, every 2 weeks Oxaliplatin, 85 mg/m2, intravenous, day 1 Leucovorin, 400 mg/m2, intravenous, day 1 Irinotecan, 150 mg/m2, intravenous, day 1 fluorouracil, 2,400 mg/m2, intravenous, day 1-2

Trial Locations (1)

05505

Asan Medical Center, Seoul

Sponsors
All Listed Sponsors
lead

Asan Medical Center

OTHER

NCT04986930 - mFOLFIRINOX With or Without Stereotactic Body Radiotherapy in Locally Advanced Pancreatic Adenocarcinoma | Biotech Hunter | Biotech Hunter